Hallmarks of cancer cell development

What is the WIN Consortium?

Pembrolizumab and indoximod for melanoma

Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030

Nivolumab for NSCLC: five years on

Avelumab for metastatic Merkel cell carcinoma after chemotherapy

Nivolumab and ipilimumab combination for advanced skin cancer

Long-term clinical outcomes and analyses of atezolizumab for mTNBC

Checkmate 067 - combined nivolumab and ipilimumab

IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors

Durable responses to avelumab in patients with Merkel cell carcinoma

Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses